Prenatal diagnosis and management of fetal supraventricular tachyarrhythmia and postnatal outcomes

Demirci, Oya; Tosun, Öykü; Bolat, Güher

doi:10.1016/j.jogoh.2022.102323

Cited by 4 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Parents were made aware of possible SVT in the neonate upcoming life as in one of the studies it was found that half of the fetus had SVT in neonatal life. 3 Nepalese Heart Journal 2023; Vol. 20(1), 57-59…”

Section: Introductionmentioning

confidence: 99%

Verapamil for treatment of Fetal Supraventricular Tachycardia

Singh,

Thakur,

Singh

et al. 2023

Nepalese Heart J.

View full text Add to dashboard Cite

Fetal arrythmia is reported to affect 1-2% of pregnancies. Besides digoxin not many drugs have been tried in treating such cases. After confirming 1:1 conduction between atrium and ventricle, no structural heart disease of fetus and normal echocardiography and ECG of mother, verapamil was given in the treatment of fetal supraventricular tachycardia. The drug crossed placenta to revert fetus SVT to sinus rhythm without harming mother. The treatment helped fetus against possible complications.

show abstract

Section: Introductionmentioning

confidence: 99%

Verapamil for treatment of Fetal Supraventricular Tachycardia

Singh,

Thakur,

Singh

et al. 2023

Nepalese Heart J.

View full text Add to dashboard Cite

show abstract

Antiarrhythmics

2022

Reactions Weekly

View full text Add to dashboard Cite

Outcome of Fetal Dysrhythmias with and without Extracardiac Anomalies

et al. 2023

View full text Add to dashboard Cite

Fetal dysrhythmias are common abnormalities, which can be categorized into three types: rhythm irregularities, tachyarrhythmias, and bradyarrhythmias. Fetal arrhythmias, especially in high-risk pregnancies, require special monitoring and treatment. The aim of this study was to assess the stillbirth and early and late neonatal mortality rates for pregnancies complicated by fetal dysrhythmias from one single tertiary referral center from 2000 to 2022. Of the 1018 fetuses with congenital heart disease, 157 (15.42%) were evaluated in this analysis. Seventy-four (46.7%) fetuses had bradyarrhythmias, 51 (32.5%) tachyarrhythmias, and 32 (20.4%) had rhythm irregularities. Additional structural heart defects were detected in 40 (25.3%) fetuses and extracardiac anomalies in 29 (18.4%) fetuses. Thirteen (8.2%) families opted for termination of the pregnancy. Eleven (7.6%), out of 144 continued pregnancies ended in spontaneous intrauterine fetal death (IUFD). Neonatal death was observed in nine cases (5.7%), whereas three (1.9%) died within the first 7 days of life. Although most intrauterine fetal deaths occurred in pregnancies with fetal bradyarrhythmia, neonatal death was observed more often in fetuses with tachyarrhythmia (8.5%). The presence of extracardiac anomalies, congenital heart disease (CHD), and Ro-antibodies are predictive factors for the occurrence of IUFD. Rhythm irregularities without any other risk factor do not present higher risks of adverse perinatal outcome.

show abstract

Prenatal diagnosis and management of fetal supraventricular tachyarrhythmia and postnatal outcomes

Cited by 4 publications

References 22 publications

Verapamil for treatment of Fetal Supraventricular Tachycardia

Verapamil for treatment of Fetal Supraventricular Tachycardia

Antiarrhythmics

Outcome of Fetal Dysrhythmias with and without Extracardiac Anomalies

Contact Info

Product

Resources

About